S&P 500   3,336.10 (-1.10%)
DOW   28,978.51 (-0.83%)
QQQ   230.30 (-1.91%)
AAPL   313.23 (-2.21%)
FB   210.43 (-1.93%)
MSFT   178.43 (-3.25%)
GOOGL   1,487.01 (-1.98%)
AMZN   2,096.81 (-2.61%)
NVDA   294.05 (-4.75%)
BABA   212.77 (-2.42%)
GE   12.26 (-2.16%)
TSLA   901.44 (+0.23%)
AMD   53.43 (-6.72%)
T   38.52 (-0.23%)
ACB   1.66 (-1.19%)
F   7.90 (-1.62%)
BAC   34.37 (-1.38%)
DIS   139.04 (-0.95%)
GILD   69.63 (+3.93%)
S&P 500   3,336.10 (-1.10%)
DOW   28,978.51 (-0.83%)
QQQ   230.30 (-1.91%)
AAPL   313.23 (-2.21%)
FB   210.43 (-1.93%)
MSFT   178.43 (-3.25%)
GOOGL   1,487.01 (-1.98%)
AMZN   2,096.81 (-2.61%)
NVDA   294.05 (-4.75%)
BABA   212.77 (-2.42%)
GE   12.26 (-2.16%)
TSLA   901.44 (+0.23%)
AMD   53.43 (-6.72%)
T   38.52 (-0.23%)
ACB   1.66 (-1.19%)
F   7.90 (-1.62%)
BAC   34.37 (-1.38%)
DIS   139.04 (-0.95%)
GILD   69.63 (+3.93%)
S&P 500   3,336.10 (-1.10%)
DOW   28,978.51 (-0.83%)
QQQ   230.30 (-1.91%)
AAPL   313.23 (-2.21%)
FB   210.43 (-1.93%)
MSFT   178.43 (-3.25%)
GOOGL   1,487.01 (-1.98%)
AMZN   2,096.81 (-2.61%)
NVDA   294.05 (-4.75%)
BABA   212.77 (-2.42%)
GE   12.26 (-2.16%)
TSLA   901.44 (+0.23%)
AMD   53.43 (-6.72%)
T   38.52 (-0.23%)
ACB   1.66 (-1.19%)
F   7.90 (-1.62%)
BAC   34.37 (-1.38%)
DIS   139.04 (-0.95%)
GILD   69.63 (+3.93%)
S&P 500   3,336.10 (-1.10%)
DOW   28,978.51 (-0.83%)
QQQ   230.30 (-1.91%)
AAPL   313.23 (-2.21%)
FB   210.43 (-1.93%)
MSFT   178.43 (-3.25%)
GOOGL   1,487.01 (-1.98%)
AMZN   2,096.81 (-2.61%)
NVDA   294.05 (-4.75%)
BABA   212.77 (-2.42%)
GE   12.26 (-2.16%)
TSLA   901.44 (+0.23%)
AMD   53.43 (-6.72%)
T   38.52 (-0.23%)
ACB   1.66 (-1.19%)
F   7.90 (-1.62%)
BAC   34.37 (-1.38%)
DIS   139.04 (-0.95%)
GILD   69.63 (+3.93%)
Log in

NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

$11.38
+0.21 (+1.88 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$10.94
Now: $11.38
$11.64
50-Day Range
$11.26
MA: $13.27
$15.52
52-Week Range
$4.14
Now: $11.38
$26.02
Volume391,009 shs
Average Volume745,455 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:MYOV
CUSIPN/A
Phone44-20-7400-3347

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.54) per share

Profitability

Net Income$-273,550,000.00

Miscellaneous

Employees86
Market Cap$1.02 billion
Next Earnings Date5/22/2020 (Estimated)
OptionableNot Optionable

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.


Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd (NYSE:MYOV) released its quarterly earnings results on Monday, February, 10th. The company reported ($0.96) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.16. View Myovant Sciences' Earnings History.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Friday, May 22nd 2020. View Earnings Estimates for Myovant Sciences.

What price target have analysts set for MYOV?

7 brokers have issued 12-month target prices for Myovant Sciences' stock. Their forecasts range from $15.00 to $34.00. On average, they expect Myovant Sciences' share price to reach $24.20 in the next year. This suggests a possible upside of 112.7% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

What is the consensus analysts' recommendation for Myovant Sciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

Has Myovant Sciences been receiving favorable news coverage?

News stories about MYOV stock have been trending extremely negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myovant Sciences earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Myovant Sciences.

Who are some of Myovant Sciences' key competitors?

What other stocks do shareholders of Myovant Sciences own?

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:
  • Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)
  • Mr. Frank L. Karbe, Chief Financial Officer (Age 51)
  • Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)
  • Ms. Julie Tran MBA, MSHR, Sr. VP of HR
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51)

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.26%), Eventide Asset Management LLC (4.60%), Victory Capital Management Inc. (2.78%), Victory Capital Management Inc. (2.75%), Lord Abbett & CO. LLC (2.08%) and FMR LLC (0.73%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

Which major investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Bank of New York Mellon Corp, Victory Capital Management Inc., Victory Capital Management Inc., Bank of America Corp DE, Platinum Investment Management Ltd., Virginia Retirement Systems ET AL and Tower Research Capital LLC TRC . Company insiders that have sold Myovant Sciences company stock in the last year include Frank Karbe, Kim Sablich and Matthew Lang. View Insider Buying and Selling for Myovant Sciences.

Which major investors are buying Myovant Sciences stock?

MYOV stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Candriam Luxembourg S.C.A., Raymond James & Associates, Oxford Asset Management LLP, Parkman Healthcare Partners LLC and Janus Henderson Group PLC. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $11.38.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $1.02 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is http://www.myovant.com/.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel